Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Purpose Chidamide (CS055/HBI-8000) is a new histone deacetylase (HDAC) inhibitor of the benzamide class currently under clinical development in cancer indications. This study reports the in vitro and in vivo antitumor characteristics of the compound.Methods Selectivity and potency of chidamide in inhibition of HDAC isotypes were analyzed by using a panel of human recombinant HDAC proteins. Tumor cell lines either in culture or inoculated in nude mice were used for the evaluation of the compound's antitumor activity. To investigate the immune cell-mediated antitumor effect, isolated peripheral blood mononuclear cells from healthy donors were treated with chidamide, and cytotoxicity and expression of relevant surface proteins were analyzed. Microarray gene expression studies were performed on peripheral white blood cells from two T-cell lymphoma patients treated with chidamide.Results Chidamide was found to be a low nanomolar inhibitor of HDAC1, 2, 3, and 10, the HDAC isotypes well documented to be associated with the malignant phenotype. Significant and broad spectrum in vitro and in vivo antitumor activity, including a wide therapeutic index, was observed. Chidamide was also shown to enhance the cytotoxic effect of human peripheral mononuclear cells ex vivo on K562 target cells, accompanied by the upregulation of proteins involved in NK cell functions. Furthermore, the expression of a number of genes involved in immune cell-mediated antitumor activity was observed to be upregulated in peripheral white blood cells from two T-cell lymphoma patients who responded to chidamide administration.Conclusions The results presented in this study provide evidence that chidamide has potential applicability for the treatment of a variety of tumor types, either as a single agent or in combination therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“suggesting a greater degree of HDAC inhibition or differing off-target effects of tucidinostat.19,20”
In the citing paper
“The frequency of grade 3 and 4 AEs was also much higher in the investigational arm of the ACE trial (75%) than that observed in E2112 (50%)”
Citations
Cites
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200 · cited 2×
“Given the known importance of histone acetylation for regulating transcription, gene expression changes resulted from HDAC inhibition by HDACi play a key role in HDACi-mediated antitumor effects [19].”
BackgroundDetermination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713 · cited 1×
“Similar results have been reported for most HDACi, regardless of chemical class [22, 23].”
ResultSaito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694 · cited 2×
“5–50 mg/kg dosedependently reduced tumor size and tumor weight, and the dose of 50 mg/kg produced similar or greater efficacy compared with the control drugs 5-fluorouracil (5-FU, 20 mg/kg) and MS-275 (25 mg/kg, which was reported as the maximum tolerated dose in xenograft models [15]).”
BackgroundMethodWeichert, W., Röske, A., Gekeler, V, Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 477
Histone Deacetylase Inhibitors: From Bench to Clinic
Paris, M., Porcelloni, M., Binaschi, M., & Fattori, D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7011408 · Cited by 367 · cited 1×
“Examples of each of these classes have entered clinical development as antitumor agents [7, 8].”
BackgroundArmeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 358 · cited 1×
“In addition, HDACi have also been shown to sensitize tumor cells to NK cell killing, for example, by inducing the expression of MHC class I-related proteins [24] and NKG2D ligand [25] on tumor cells.”
BackgroundMunshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L., Ismail, S., Stevens, C., & Meyn, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2088 · Cited by 345 · cited 1×
“repair [20] and many non-histone proteins [21], which make contributions to HDACi-mediated antitumor effects”
BackgroundExpression profile of class I histone deacetylases in human cancer tissues
Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., et al. (2007) · Oncology Reports · doi:10.3892/or.18.4.769 · Cited by 341
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332 · cited 1×
“Chidamide is more potent than MS-275 against these enzymes and also compares favorably to the published data for another HDACi of the benzamide class, MGCD0103 [16, 17].”
Self-citationSkov, S., Pedersen, M. T., Andresen, L., Thor Straten, P., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 259 · cited 1×
“In addition, HDACi have also been shown to sensitize tumor cells to NK cell killing, for example, by inducing the expression of MHC class I-related proteins [24] and NKG2D ligand [25] on tumor cells.”
Background
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Indole: A privileged scaffold for the design of anti-cancer agents
Wan, Y., Li, Y., Yan, C., Yan, M., & Tang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111691 · Cited by 516
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
“Promising results are expected from other approved HDAC inhibitors: romidepsin [136], belinostat [137], panobinostat [138], and chidamide [139].”
BackgroundShi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., Ke, X., Huang, H., Shen, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv237 · Cited by 385
Self-citationJiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30164-0 · Cited by 270
Self-citation
Metadata
- Authors
- Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P.
- Affiliations
- HUYABIO International, LLC (United States) (US)
- Shenzhen Chipscreen Biosciences Co. (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- ORCID
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2011-11-12
- Volume
- 69
- Issue
- 4
- Pages
- 901-909
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2033582950
- Cited by
- 303
- References
- 22
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 34 · 2023: 33 · 2022: 34 · 2021: 43 · 2020: 33 · 2019: 18 · 2018: 21 · 2017: 12 · 2016: 12 · 2015: 4 · 2014: 4 · 2013: 4 · 2012: 5
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- chidamide, histone deacetylase inhibitors, HDAC1, HDAC2, HDAC3, HDAC10, anticancer activity, NK cell function, T-cell lymphoma, K562 cells, peripheral blood mononuclear cells, gene expression profiling, combination therapy
- MeSH terms
- Acetylation, Aminopyridines, Animals, Benzamides, Cytotoxicity, Immunologic, Female, Histone Deacetylases, Histones, Humans, Immunity, Cellular, Isoenzymes, Killer Cells, Natural, Mice, Inbred BALB C, Mice, Nude, Neoplasms, Gene Expression, Lymphoma, T-Cell, K562 Cells, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Growth Processes, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. https://app.cochat.ai/papers/10.1007/s00280-011-1766-x
- The paper
- Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P. (2012). Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-011-1766-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.